What To Know
- Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.
- (“Radication”), a medical device company, announced today that it was granted additional patents in the US and Japan, protecting key technological developments of its radiation shielding device.
Radiaction Medical Ltd. (“Radication”), a medical device company, announced today that it was granted additional patents in the US and Japan, protecting key technological developments of its radiation shielding device.
Radiaction Medical, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures. Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection. The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.
Tested in a real-life clinical environments, the system demonstrated an entire room scattered radiation reduction performance of 91.2% in IC procedures and 93.3% in EP procedures. These rates are on par with the protection provided to the body’s core by lead aprons. Importantly, Radiaction Medical is protecting heads, arms, long bones and feet which are outside of the lead apron and are exposed and subjected to harmful cumulative radiation damage. This clinical experience also demonstrated high physician satisfaction with the integration into the clinical workflow.
Radiaction Medical has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device. The on-going advancements include various automation features, that allow smooth integration into clinical workflow and superior shielding of medical staff.
“We are pleased by the ongoing validation of our radiation shielding technology’s differentiation,” said Mr. Jonathan Yifat, CEO of Radiaction Medical. “As we are nearing commercialization, these patents strengthen our strategic IP assets and further our mission to provide a safe environment for healthcare teams in the interventional suite,” added Mr. Yifat.
In addition, the company successfully gained CE mark under the MDR with Emergo, paving the way for European initial installations at selected sites.
